Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + furosemide + hypertonic saline solution
- Development stage
- Unknown
- Lead developer
- Università degli studi di Palermo
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of dapagliflozin, furosemide, and hypertonic saline solution is a therapeutic regimen being investigated by the University of Palermo in the DAPA-TONIC clinical trial. This approach targets acute decompensated heart failure (ADHF) in patients with type 2 diabetes mellitus. Dapagliflozin, an SGLT2 inhibitor, reduces sodium and glucose reabsorption in the proximal tubule, while furosemide inhibits the NKCC2 transporter in the loop of Henle. The addition of small-volume hypertonic saline solution (HSS) acts as an osmotic agent, shifting fluid into the intravascular space to improve renal perfusion and sodium delivery to the nephron. This triple combination aims to maximize fluid removal (diuresis) and sodium excretion (natriuresis), potentially leading to faster weight reduction and shorter hospital stays without adversely affecting renal function.
- Other names
- hypertonic saline solution-University of Palermo-heart failure (acute)-type 2 diabetes mellitusDAPA-TONIC regimen
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)NKCC2 (Sodium-potassium-chloride cotransporter 2)
Beyond the preview
Go deeper on dapagliflozin + furosemide + hypertonic saline solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + furosemide + hypertonic saline solution.